Motivation:Togatherinformationaboutavailabledatabases andchemoinformaticsmethodsforpredictionofproperties relevanttothedrugdiscoveryandoptimizationprocess.
INTRODUCTION
Chemoinformatics (Blake, 2000; Olsson and Oprea, 2001; Kubinyi, 2003 ) is a rapidly growing field, with a huge application potential. Chemoinformatics concerns the gathering and systematic use of chemical information, and the use of those data to predict the behavior of unknown compounds in silico.
The word chemoinformatics is rather new, but papers that fall under this field date back to the mid 1960s, where Structure-Activity Relationships (SAR) were proposed based on the work of Hansch and Fujita (1964) and Fujita et al. (1964) and earlier work of Hammett and Taft. The first textbooks on chemoinformics have been published * To whom correspondence should be addressed recently (Leach and Gillet, 2003; Gasteiger and Engel, 2003; Gasteiger, 2003; Bajorath, 2004) .
The related field bioinformatics (Durbin et al., 1998; Baldi and Brunak, 2001; Mount, 2001; Orengo et al., 2002; Lengauer, 2002) was fully established in the nineties, and has become an integrated activity in most major pharmaceutical companies. The basis behind the success of bioinformatics was the access to a vast amount of experimental data, together with the structured nature of genetic information. Several authors have recently published reviews on the use of bioand chemoinformatics methods in drug discovery process (Stahura and Bajorath, 2002; Hopkins and Groom, 2002; Golden, 2003) .
The availability of experimental data relevant to chemoinformatics modeling is, however, much more restricted. In fact, most of the chemical information reside in the private domain. If the success of the bioinformatics area should be mimicked, the availability of new experimental data will be an absolute necessity for developing efficient and robust models for prediction of various properties (Beresford et al., 2002) .
Implementing, handling and searching chemical databases is a crucial aspect of chemoinformatics (Miller, 2002) . Chemical database techniques and data mining methods will improve as this field evolves, also due to more implementation of new data structures (Miled et al., 2003) . Methods for full text data mining are likely to be become very powerful in the years to come, and will presumably play a highly important role in the general area of chemoinformatics. A new XML (Extensible Markup Language) based approach for managing molecular information, Chemical Markup Language (CML), was proposed by Murray-Rust and Rzespa (1999) . Figure 1 shows the number of references to the words "bioinformatics", "chemoinformatics", "chemogenomics" and "metabonomics" in PubMed from 1992 to 2004. It is seen that the present trend for chemoinformatics resembles the trend in bioinformatics five to ten years ago. It should be mentioned that this graph is based on one database only, PubMed, and is intended to give an idea about the development in publishing frequency in these areas, and not as a complete overview.
It is clear that the drug discovery and optimization process is undergoing very significant changes. Many more hits are found than previously, especially due to the advances gained in combinatorial chemistry Gordon et al., 1994) and high throughput screening (HTS). The approach used in drug discovery has been linear with respect to various relevant properties, but more parallel approaches are evolving, where not only the potency (activity) and selectivity of the lead is examined at an early stage, but also other key properties. Many of the compounds drawn out of combinatorial libraries may look promising at first, but they fail at later stages in the drug discovery process due to undesired properties. A compound can for example be feasible based on molecular structure, but due to aggregation, limited solubility or limited uptake in the human organism it is not useful as a drug. Many pharmaceutical companies might even be repeating the same mistakes, due to these problems. Methods for assessing these properties at a very early stage, both experimentally and computationally, are thus highly desirable. This is expected to lower the cost of drug discovery and optimization significantly, and hopefully provide an increased number of useful leads. In cases where a lead has sufficiently high activity, but various properties need to be improved, chemoinformatics methods could be used to modify substructures within the lead space with minimal effect on the activity profile .
Much improvement has occurred concerning techniques for in vitro measurements of various properties, and in models used for accessing how well a given compound does absorb from the gastrointestinal tract (GIT) into the blood stream or its ability to cross the blood-brain-barrier (BBB) . In most cases in vitro measurements are carried out using different cell models, human or animal. For measuring permeability, and thus absorption, the use of artificial membranes, called PAMPA (Parallel Artificial Membrane Permeability Assay) has become a popular alternative to the CACO-2 (human colon carcinoma) cell line . The cost of each measurement using PAMPA is 1/20 of that of CACO-2, seemingly with comparable accuracy (van de Waterbeemd et al., 2001) . PAMPA is, however, only useful for measuring passive permeability. For in vitro studies of liver toxicity, the rat hepatoma cell line is a well characterized and evaluated method, which is often followed up by human hepatoma cell line studies (van de Waterbeemd et al., 2001) . Toxicogenomic studies using microarray expression techniques have also become increasingly important. Major concerns in toxicological studies, are multiple endpoints, dose-response relationships and selection of endpoints. Other important aspects are purity of drugs, protein binding, and metabolic stability among others.
Likewise, various computational methods are evolving rapidly at present. Computational techniques used to search through chemical libraries and databases, so-called virtual screening methods, have become increasingly popular in drug discovery Böhm and Schneider, 2000) . A whole range of computational techniques are used for searching for molecular similarities and dissimilarities (Sello, 1998; Willett, 2000; Bajorath, 2002; , for extracting information about pharmacophores (structural models of targets or binding sites) from compound libraries (Hopfinger and Duca, 2000) , for prediction of properties, for studying molecular interactions at the atomic level, among other things (Miller, 2002) . Chemoinformatics is strongly linked to computational chemistry and molecular modeling (Burkert and Allinger, 1982; Jensen, 1999; Cramer, 2002) . Molecular modeling methods are particularly useful for conducting conformational analysis of molecules, and for accessing the strength of intermolecular interactions.
Newly established fields like chemogenomics (or chemical genomics), metabonomics and metabolomics also play an increasingly important role in modern drug discovery and development. Chemogenomics (Browne et al., 2002) deals with interactions between chemical compounds and living systems in terms of induced genomic response. In metabonomics (Nicholson and Wilson, 2003) relatively low-molecular weight materials produced during genomic expression within a cell are studied, normally by use of 1 H-NMR spectroscopy and multivariate data analysis (chemometrics) (Geladi and Kowalski, 1986b,a) . It has been shown to be an useful tool for understanding drug efficacy and toxicity. Metabolomics is similar to metabonomics, but where metabonomics deals with integrated, multicellular, biological systems, metabolomics deals with simple cell systems.
This review presents an extensive and thorough overview of small molecule databases relevant to drug discovery, and methods for classifying chemical compounds as being drug-like and/or lead-like. A brief overview of various methods for predicting ADMET (Adsorption, Distribution, Metabolism, Excretion and Toxicity) properties, blood-brain barrier penetration and key physico-chemical properties is also given, but it must be stressed that this overview is by no means complete. References are given to more detailed review papers for the various properties.
The fundamental behavior of substances is governed by intermolecular interactions at various levels. Physicochemical properties of drug molecules are mostly governed by the interactions between the drug molecules and the surrounding aqueous environment. Potency of drugs depends on how well a given drug molecule (ligand) fits into a target, and how strong the interactions between the ligand and the target are, often studied with computational methods, e.g. docking and scoring methods. ADMET properties depend on how the drug molecule interacts with a large number macromolecules in the human organism. In cases where a patient uses more than one drug, drug-drug interactions are also of importance, and such interactions are unfortunately often ignored. The human organism is an immensely complicated system, but modeling of properties can be accomplished by studying various subsystems and their interactions using a broad range of computational and experimental methods. In a recent paper Macchiarulo et al. (2004) have studied cross interactions between enzymes and small molecules in a cell, that are caused by similarities in the molecular structures of the metabolites (small molecules) and the flexibility in binding at the active sites of the enzymes. Based on their results they propose that HTS should not only involve a selection of small molecules, but also a panel of proteins to test for cross-reactivity.
DATABASES
The availability of reliable experimental data and basic structural information is crucial for successful modeling work. In this section various databases relevant to drug discovery and development are discussed, including databases for available organic compounds, screening compounds, medicinal agents (drugs), as well as databases with ADMET properties and physico-chemical properties. A few protein databases are also mentioned.
An overview of the databases and key features is given in Table 1 , and the type of properties provided is listed in Table 2 . Most of the databases provide 1-dimensional (1D), 2-dimensional (2D) and 3-dimensional (3D) structural information (see below for further detail on molecular descriptors). The 1D coding is either given in the SDFile format from MDL Information Systems or as SMILES (Simplified Molecular Input Line Entry Specification) strings (Weininger, 1988) . In cases where only 1D and 2D information is given, several programs for generating 3D structures from 2D structures are available. One should, however, bear in mind that due to conformational flexibility many 3D structures (equilibrium conformations) may exist for each molecule. Examples of 1D, 2D and 3D structures are shown on Figure 2 . Fig. 2 . Structural information for a molecule can be given as a 1D SMILES string, a 2D drawing or a 3D representation. The SMILES string and the 2D drawing contain information about which atoms are bound to one another, and the 3D representation shows how the atoms are located geometrically in relation to one another. The used atomic coordinates are shown behind the 3D picture.
General small molecule and screening compound databases
The best known database for synthetic organic and inorganic compounds is the Available Chemicals Directory (ACD) 1 , which currently includes approximately 300,000 unique substances. ACD is often used for representing non-drugs in model development, and although some compounds within ACD may be biologically active, the majority of compounds are not. The Chemicals Available for Purchase (CAP) database contains similar information, where the CAP Reagents database currently has about 240,000 molecular structures and CAP Complete approximately 1.6 million compounds. A new version of the Spresi database, SPRESI web , contains more than 4.5 million molecules, including various physical properties, and 3.5 million 1 Databases and computer programs are listed in alphabetical order before the references. Some of the databases and programs are represented by an ordinary reference, and are not included in this list.
reactions. The physical property information is, however, not well organized within the Spresi database.
A number of databases have been developed especially for screening purposes. Three main catalogs, previously being part of ACD, the SALOR (Sigma-Aldrich Library of Rare Chemicals), Maybridge and Bionet, are now available through MDL Screening Compounds Directory (MDL SCD). The SPECSnet database contains screening compounds, building blocks and natural products provided by SPECS.
Databases for medicinal agents
The three main database collections of drug molecules are the Comprehensive Medical Chemistry database (CMC), MDL Drug Data Report (MDDR) and the Derwent Word Drug Index (WDI). CMC contains presently 8,473 drug compounds, and is updated annually with compounds identified for the first time in the United States Approved Names (USAN) list. The CMC database also includes information about drug class, and measured or estimated values for the acid-base dissociation constant (pK a ) and the octanol/water partition coefficient (logP ). For logP , 120 experimental and 8,300 calculated records are provided, and for pK a 1,200 measured records are given. The MDDR contains 132,726 drugs launched and under development, collected from the patent literature and other relevant sources. MDDR is updated monthly, which adds up to app. 10,000 new compounds per year, and includes information about drug class, and drug activity in qualitative terms as well. WDI contains around 73,000 marketed drugs and drugs under development, with each record classified by drug activity, mechanism of action, treatment, among other factors. The Derwent Drug File is a highly focused database of selected journal articles and conference reports on all aspects of drug development.
There are a number of other available drug databases. The National Cancer Institute database (NCI) contains 213,628 compounds, and is made up of four publicly available NCI databases, including both the AIDS and the Cancer databases. The MedChem database consists of 48,500 compounds, 67,000 measured logP values, 13,700 measured pK a values and 19,000 pharmacological (drug) activities. According to the providers of the MedChem database, all available data for logP and pK a have been gathered from the literature. In addition, the database includes a sorted list only containing those measurements carried out with high quality methods. The MedChem database also contains a collection of biological and physico-chemical data intended for QSPR (Quantitative Structure-Property Relationship) modeling, and software for calculating logP values (ClogP ). 
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a ql means that drug activity is given in qualitative terms. 
Databases for ADMET properties of drugs
The MDL Metabolite database contains information about metabolism pathways for xenobiotic compounds and biotransformations (primary medicinal agents) and experimental data from in vivo and in vitro studies. The database includes more than 10,000 parent compounds, over 64,000 biotransformations and over 40,000 molecules (parent compounds, intermediates and final metabolites). Metabolism data are also found in the Accelrys' Metabolism and Biotransformation databases. The Metabolism database covers vertebrates (animals), invertebrates, and plants. This databases contains 4,101 parent compounds, 30,000 transformations and is being extended to 40,000 transformations. The Accelrys' Biotransformation database, on the other hand, is a stand-alone database for vertebrates only, containing 1,744 unique parent compounds, and 9,809 transformations. The MDL Toxicity database includes more than 158,000 chemical substances compiled from several major sources, where around 65% are drugs and drug development compounds. The database contains six categories of data, i.e. acute toxicity, mutagenicity, skin/eye irritation, tumorigenicity, reproductive effects and multiple dose effects. It also contains detailed information about how the in vivo and in vitro experiments were carried out, including species of organism or tissue studied, dose, etc. The DSSTox project (Distributed Structure-Searchable Toxicity Public Database Network) (Richard and Williams, 2002 ) is a forum for publishing toxicity data, presently including databases for carcinogenicity in various animals, as well as acute toxicity.
The ToxExpress Reference Database is a toxicogenomic database, which contains gene expression profiles from known toxicants. This database is built on in vivo and in vitro studies of exposure to toxicants, and around 110 compounds have been profiled.
Other databases that might be of interest, although primarily focused on environmental and occupational health issues, are the TSCA93 database, containing over 100,000 substances, and the TOXicology Data NETwork (TOXNET) database cluster.
Other important small molecule databases
The ACD/Labs Physico-Chemical Property databases contain a variety of physico-chemical data for organic substances, including experimental logP for 18,400 compounds, over 31,000 measured pK a values for 16,000 compounds and aqueous solubility (logS) for 5,000 compounds. Another collection of experimental data is the Physical Properties Database (PHYSPROP) from Syracuse Research Corporation (SRC), which counts 13,250 measured logP values, 1,652 pK a values and 6,340 records for aqueous solubility. Both ACD/Labs and SRC market software for prediction of these and other properties. A third database, the AQUASOL dATAbASE, contains aqueous solubilities for almost 6,000 compounds.
There are other important databases for small molecules. CrossFire Beilstein contains more than 8 million organic compounds, over 9 million reactions, a variety of properties, including various physical properties, pharmacodynamics, and environmental toxicity. This database contains over 500,000 bioactive compounds. Other important collections of physical properties of organic compounds are CRC (Lide, 2003) 
Protein databases and ligand information
In this context, we would also like to mention a few relevant macromolecular and crystallographic databases with drug-discovery relevant information. The Protein Data Bank (PDB) is the main source for available protein crystal structures and structural information obtained with NMR spectroscopy, currently with more than 28,000 structures, and a weekly growth of about 100 structures. The Cambridge Structural Database (CSD) is the most comprehensive collection of crystallographic data for small molecules, containing around 305,000 structures. Figure 3 shows the evolution in number of structures within PDB and CSD over the last twelve years. Although CSD has much larger number of entries, the relative growth rate within PDB is higher, which shows clearly the increased focus on protein structure determination world wide (structural genomics).
PDB contains a number of useful sub-databases, including a Target Registration Database. Relibase Günther et al., 2003 ) is a powerful data mining tool which utilizes structural information about proteinligand complexes within PDB for comprehensive analysis of protein-ligand interactions. Relibase+ is an improved version of Relibase with number of additional features, like protein-protein interaction searching and crystal packing module for studying crystallographic effects around ligand binding sites. The LIGAND database (Goto et al., 1998 (Goto et al., , 2002 ) is a chemical database for enzyme reactions, including information about structures of metabolites and other chemical compounds, their reactions in biological pathways, and nomenclature of enzymes. Ji et al. (2003) recently published an overview paper on various data collections for proteins associated with drug therapeutic effects, adverse reactions and ADME available over the internet.
A number of databases containing protein-protein interaction data are available, including Database of Interacting Proteins (DIP) (Xenearios et al., 2002) , Biomolecular Interaction Network Database (BIND) (Bader et al., 2003) , Molecular Interaction Database (MINT) (Zanzoni et al., 2002) , Comprehensive Yeast Protein Genome Database (MIPS) (Mewes et al., 2002) , Yeast Proteome Database (YPD) (Hodges et al., 1999; Costanzo et al., 2000) , the IntAct database (Hermjakob et al., 2004) and Human Protein Reference Database (HPRD) (Peri et al., 2003) , among others. Protein-protein interaction databases are collections of information about actual protein-protein contacts or complex associations within the proteome of specific organisms, in particularly in yeast, but also in humans, fruitfly and other organisms.
DESCRIPTORS USED FOR CHEMICAL STRUCTURES
In chemoinformatics the structural features of the individual molecules are described by various parameters derived from the molecular structure, so-called descriptors (Todeschini and Consonni, 2000) . The simplest types are constitutional (1D) or topological (2D) descriptors, describing the types of atoms, functional groups, or types and order of the chemical bonds within the molecules. Ghose atom types (Viswanadhan et al., 1989) , CONCORD atom types, ISIS keys (MDL keys) (Durant et al., 2002) , and various other atom/bond indices discussed in the following section, are examples of such descriptors. Physico-chemical properties are often used as descriptors as well.
The ISIS keys and CONCORD atom types are often referred to as fingerprint methods, and were for example used when training of neural networks (Frimurer et al., 2000) for compound classification. ISIS keys are a set of codes which represent the presence of certain functional groups and other structural features in the molecules, and CONCORD atom types are generated by assigning up to six atom-type codes available within the CONCORD program (Pearlman, 2000) to each atom.
In QSAR (Quantitative Structure-Activity Relationship) and QSPR modeling, constitutional and topological descriptors are combined with more complicated descriptors, representing the 3D structure of the molecules. This includes various geometrical descriptors, and most importantly a variety of electrostatic and quantum chemical descriptors. The electrostatic descriptors are parameters which depend on the charge distribution within the molecule, including the dipole moment. Examples of a quantum chemically derived descriptors are various energy values, like ionization energies, HOMO-LUMO gap, etc. Similarly descriptors derived from molecular mechanics can be used (Dyekjaer et al., 2002) . A variety of different types of descriptors used in QSAR and QSPR are discussed by Karelson (2000) .
QSAR and QSPR models are empirical equations, used for estimating various properties of molecules, and have the form
where P is the property of interest, a, b, c,· · · are regression coefficients and D 1 , D 2 , D 3 , · · · are the descriptors. So-called 3D QSAR methods differ somewhat from traditional QSAR methods. The CoMFA (Comparative Molecular Field Analysis) (Cramer III et al., 1988) approach, one of the most popular 3D QSAR methods, uses steric and electrostatic interaction energies between probe atoms and the molecules as descriptors. In the VolSurf method a similar approach is used, where descriptors are generated from molecular interaction fields calculated by the GRID program (Goodford, 1985) .
REDUNDANCY OF DATA SETS
When using data extracted from large databases to train and test data driven prediction tools, the redundancy, completeness and representativeness of the underlying data sets is extremely important. The redundancy affects strongly the evaluation of the predictive performance, and also, most importantly the bias of the method toward specific, overrepresented subclasses of compounds.
Within the general bioinformatics area this is an issue that has been dealt with in great detail. It is well known that if a protein structure prediction algorithm is tested on sequences and structures which are highly similar to the sequences and structures used to train it, the predictive performance is significantly overestimated (Sander and Schneider, 1991) . Therefore methods have been constructed for cleaning data sets for examples that are "too easy", such that the performance of the algorithm on novel data will be estimated in a more reliable manner. One needs obviously to define the similarity measure between the data objects under consideration, for amino acid sequences one typically uses alignment techniques as the metric for quantitative, pairwise comparison (Hobohm et al., 1992) . Techniques have also been developed for redundancy reduction of sequences containing functional sites, such as signal peptide cleavage sites in secreted proteins (Nielsen et al., 1996) or translation initiation sites in mRNA sequences (Pedersen and Nielsen, 1997) .
In this respect chemoinformatics is still in its infancy compared to the thorough validation methods used in bioinformatics. For chemoinformatics applications, redundancy within databases can affect the learning capabilities of neural networks, decision trees and other methods, whereas redundancy between different databases generally introduces noise and reduces the discriminating power of the model.
Redundancy in this context means that the compounds in their vectors, component for component, are similar. Similarity of the chemical compounds within a data set can lead to over-fitting of a model, such that predictions for compounds similar to those used in the training set are excellent, but for different compounds the predictions are not accurate to the same level. There are several examples of compound clustering techniques, where the Tanimoto coefficient (Patterson et al., 1996) has been used as the metric quantifying the similarity between compounds, normally with the goal of identifying leads by similarity, or for increasing the diversity of libraries used for screening (Reynolds et al., 1998 (Reynolds et al., , 2001 Voigt et al., 2001; Willett, 2003) . The Tanimoto coefficient, T , compares binary fingerprint vectors, and is defined as,
where N xy is the number of 1 bits shared in the fingerprints of molecules x and y, N x the number of 1 bits in the fingerprint of molecule x, and, N y the number of 1 bits in the fingerprint of molecule y. A Tanimoto coefficient approaching zero indicates that the compounds being compared are very different, while a Tanimoto coefficient approaching one indicates that they are very similar.
In the drug-likeness predictor developed by Frimurer et al. (2000) the concept of redundancy reduction normally used within bioinformatics, was transferred to compound data extracted from MDDR and ACD. In this case the compounds were represented by CONCORD atom types and the Tanimoto coefficient (Patterson et al., 1996) was used to calculate the similarity between any two compounds. Using a given threshold for maximal similarity in terms of Tanimoto coefficient of say, 0.85, the redundancy in a data set can be reduced to a well defined level. This type of technique also allows for the creation of common benchmark principles, and could replace frozen benchmark data sets, which often become outdated as databases grow over time. The performance of prediction techniques developed on different data sets can therefore be compared in a fair manner, despite the fact that the underlying data sets differ in size.
In most of the chemoinformatics applications developed so far this kind of data set cleaning has not been carried out. Instead test sets have been selected randomly from large, overall data sets, thereby introducing many cases where highly similar pairs of examples are found both in the training and test parts of the data sets. The estimation of the predictive performance is therefore much more conservative in the work of Frimurer et al., while it may be too high for some of the prediction tools where the split between training and test data has been established just by random selection.
Note that similarity to a neural network is somewhat different from molecular similarity, because the network can correlate all the vector components with each other in a nonlinear fashion. Two very different compounds may appear very similar for a neural net in terms of functionality, while two quite similar compounds can be interpreted as having different properties. A redundant data set will typically not constrain the network weight structure as much as a nonredundant data set. Nonredundant data from complete and representative data sets will therefore in most cases lead to well-performing predictors, even if the weights/training examples ratio is larger.
METHODS FOR CLASSIFICATION OF DRUG-LIKE STRUCTURES
Several methods have been developed to determine the suitability of compounds to be used as drugs (pharmaceuticals), based on knowledge about the molecular structure and key physical properties. Reviews about a variety of methods have been published recently (Walters and Murcko, 2002; Clark and Pickett, 2000; Muegge, 2003) .
The task is to select compounds from combinatorial libraries in such a way that the probability of identifying a new drug that will make it to the market is optimized. To minimize the probability of leaving out potential drugs in the HTS, it is important to ensure adequate diversity of the molecular structures used (Gillet et al., 1999) . A variety of methods for compound selection have been proposed, ranging from simple intuitive to advanced computational methods.
Intuitive and graphical methods
Many researchers have developed simple counting methods, and a highly popular method is the 'rule of five' proposed by Lipinski et al. (1997) . Although the 'rule of five' originally addresses the possibility, or risk, for poor absorption or permeation, based on molecular weight (MW), the octanolwater partition coefficient (logP , also called lipophilicity), number of hydrogen bond donors (HBD) and acceptors (HBA), respectively, it has been widely used to distinguish between drug-like and non-drug-like compounds. A number of databases have included Lipinskis' 'rule of five' data for each compound, using calculated values for logP . This is the case for SPECS, MDL SCD, ACD, ACD/Labs PhysicoChemical databases. Frimurer et al. (2000) performed a detailed, quantitative analysis assessment of the predictive value of Lipinskis' 'rule of five'. It was found that the correlation coefficient is close to zero, in fact slightly negative, when evaluated on a nonredundant data set. Oprea (2000) also discusses drug-related chemical databases and the performance of the 'rule of five'. He concludes that the 'rule of five' does not distinguish between 'drugs' and 'non-drugs', because the distribution of the parameters used does not differ significantly between these two groups of compounds. The problem with the 'rule of five' is that it represents conditions which are necessary, but not sufficient for a drug molecule. Many (in fact most) of the molecules which fulfill these conditions are not drug molecules. The work of Lipinski has had, however, a tremendous pioneering value concerning quantitative evaluation of 'drug-likeness' of chemical structures. Muegge et al. (2001) proposed a simple selection scheme for drug-likeness based on the presence of certain functional groups, pharmacophore points, in the molecule. This method and other methods using functional group filters are significantly less accurate than the various machine learning methods discussed below, see Table 3 .
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Chemistry space, or chemography, methods are somewhat similar, and are based on the hypothesis that drug-like molecules share certain properties, and thus cluster in graphical representations. Analysis of how well molecular diversity is captured using a variety of descriptors was done by Cummins et al. (1996) , Xu and Stevenson (2000) and Feher and Schmidt (2003) who examined the difference in property distribution between drugs, natural products and non-drugs. Oprea and Gottfries (2001a,b) ; Oprea et al. (2002) ; Oprea (2003) have developed a method called ChemGPS, where molecules are mapped into a space using principal component analysis (PCA), where a so-called drug-like chemistry space is placed in the center of the graph, surrounded by a non-drug-like space. Satellites, molecules having extreme outlier values in one or more of the dimensions of interest, are intentionally placed in the nondrug-like space. Examples of satellites are molecules like iohexol, phenyladamantane, benzene, and also the non-druglike drug erythromycin. They used molecular descriptors obtained with the VolSurf method, along with a variety of other descriptors in their work. Brüstle et al. (2002) proposed a method for evaluating a numerical index for drug-likeness. They proposed a range of new molecular descriptors obtained from semiempirical molecular orbital (AM1) calculations, calculated Principal Components (PCs) based on these descriptors, and used one of the PCs as a numerical index. The authors also used the proposed descriptors to develop QSPR models for a number of physico-chemical properties, including logP and aqueous solubility.
Machine learning methods
Several prediction methods using neural networks (NN) have been developed. These include work by Ajay et al. (1998) , Sadowski and Kubinyi (1998) , Frimurer et al. (2000) , Muegge et al. (2001) , Murcia-Soler et al. (2003) and Takaoka et al. (2003) . Most of these methods give relatively good predictions for drug-likeness, with the exception of the methods by Muegge et al. (2001) and Takaoka et al. (2003) . As shown in Table 3 , the methods differ in the type of NN architecture and descriptors used, and, most importantly, they use different data sets of drug molecules. The most significant difference concerns the data used to test and train the networks as discussed in the section about redundancy of data sets, and to a lesser degree the choice of descriptors for identifying the chemical structures. Ford et al. (2004) have developed an NN method for predicting if compounds are active as protein kinase ligands or not, where they used the drug-likeness method of Ajay et al. (1998) to remove unsuitable compounds on forehand. Like in the work by Frimurer et al. (2000) they use Tanimoto coefficient for establishing a diverse training set.
Ajay et al. use the so-called ISIS keys, and various other molecular properties, including those proposed in the 'rule of five', as descriptors. The descriptors used by Sadowski and Kubinyi are the atom types of Ghose (Viswanadhan et al., 1989) , originally developed for the prediction of logP . Frimurer et al. use the so-called CONCORD atom types as descriptors. In this work the descriptor selection procedure is also inverted, in the sense, that the weights in the trained NNs are inspected after training was completed. Thereby one may obtain a ranking of the importance of different descriptors for prediction tasks like drug-likeness. Obviously, such ranking cannot reveal the correlations between descriptors which may be highly important for the classification performance. The power of the NNs is that they can take such correlations into account, but they can be difficult to visualize or describe in detail. Murcia-Soler et al. (2003) assign probabilities for the ability of each molecule to act as a drug in their method. They use various topological indices as descriptors, reflecting types of atoms and chemical bonds in the molecules. Their paper contains a detailed and interesting analysis of the performance on training, test and validation data sets, see Table 3 . Takaoka et al. (2003) developed an NN method, by assigning compound scores for drug-likeness and easy of synthesis based on chemists' intuition. Their method predicts the drug-likeness of drug molecules with 80% accuracy, but the accuracy of the prediction of non-drug-likeness is hard to assess.
Wagener and van Geerestein (2000) developed a quite successful method using decision trees. The first step in their method is similar to the method by Muegge et al. (2001) , where the molecules are sorted based on which key functional groups they contain. Going through several steps, the connectivity of the atoms in each functional group is determined and atom types are assigned, using the atom types of Ghose. This basic classification is then used as an input (leaf note) in a decision tree, which is trained to determine if a compound is drug-like or non-drug-like. To increase the accuracy, a technique called boosting can be used, where weights are assigned to each data point in the training set, and optimized in such a way that they reflect the importance of each data point. By including misclassification costs in the training of the tree, the predictions can be improved even more. Gillet et al. (1998) proposed a method which uses a genetic algorithm (GA), using weights of various properties obtained from substructural analysis. Using the properties from 'rule of five' and various topological indices as descriptors, the molecules are sorted and ranked, and from these results a score is calculated. It is seen that drugs and non-drugs have different distributions of scores, with some overlap. Also the distribution varies for different types of drugs. Anzali et al. (2001) developed a QSAR type method for predicting biological activities, with the computer system PASS (prediction of activity spectra for substances). Both data for drugs and non-drugs were used in the training of the model, and subsequently used for discriminating between drugs and non-drugs.
The NN, decision trees, GA and QSAR methods are classified as machine learning, whereas 'rule of five' and functional group filters are simple intuitive methods. A short overview of the reported predictive capability of the various methods is given in Table 3 . It is seen that the NN methods and the decision tree methods give the best results. As discussed previously, it is difficult to compare the different NN methods in quantitative terms, due to differences in size and redundancy of the data sets used to train and test the methods.
Lead-likeness
Another possibility is to determine whether a molecule is lead-like rather than drug-like. As discussed by Hann et al. (2001) it is often not feasible to optimize the drug-like molecules by adding functional groups, as the molecules then become too large and over-functionalized. Instead one could target new leads with computerized methods, and in such a way give additional flexibility in targeting new potential drugs.
According to not much information about molecular structures of leads is available in the literature. In their paper, several lead structures are given, and an analysis of the difference between leads and drugs is presented. According to their analysis, drugs have higher molecular weight, higher lipophilicity, additional rotational bonds, only slightly higher number of hydrogenbond acceptors, and the same number of hydrogen-bond donors compared to leads. As pointed out by the authors, this analysis contains too few molecules to be statistically significant, but it indicates useful trends. Similar trends are also observed by Hann et al. (2001) . The design of lead-like combinatorial libraries is also discussed by Teague et al. (1999) , and Oprea conducted studies of chemical space navigation of lead molecules (Oprea, 2002a) and their properties (Oprea, 2002b) . Various methods for ranking molecules in lead-discovery programs are discussed by Wilton et al. (2003) , including trend vectors, substructural analysis, bioactive profiles and binary kernel discrimination.
PREDICTION OF PROPERTIES ADMET properties
ADMET properties stand for absorption, distribution, metabolism, excretion and toxicity of drugs in the human organism. In recent years increased attention has been put into modeling these properties, but still there is a lack of reliable models. One of the first attempts to address the modeling of one these properties, the intestinal absorption, was the 'rule of five' proposed by Lipinski et al. (1997) . A number a review articles on ADMET properties have been published recently (Beresford et al., 2002; Ekins et al., 2002; van de Waterbeemd and Gifford, 2003; Livingstone, 2003) . Boobis et al. (2002) made an expert report on the state of models for prediction of ADMET properties. Boobis et al. (2002) and van de Waterbeemd and Gifford (2003) give a fairly detailed overview of methods and computer programs for prediction of ADMET properties.
One of the major problems concerning modeling of ADMET properties is the lack of reliable experimental data for training the models. For metabolism and toxicity databases are available, but for the other properties experimental information is more scarce. A number of programs for modeling of ADMET properties have been developed recently, and ADMET modules have been included in some examples of molecular modeling software. Only models for absorption are discussed in greater detail here, whereas modeling of the other ADMET properties is only discussed briefly, with references to recent reviews. Figure 4 shows how ADMET properties relate to targets and diseases from a chemoinformatics perspective.
Absorption According to Beresford et al. (2002) reasonable models exist for intestinal absorption and blood-brain-barrier (BBB) penetration. It is, however, important to bear in mind that the reason for low oral bioavailability is often not due to poor overall absorption, but due to limited first pass through the gut wall membrane. Recently, van de Waterbeemd et al. uses an absorption model proposed by Grass (1997) , and later improved by Norris et al. (2000) , and GastroPlus T M uses the ACAT (Advanced Compartmental Absorption and Transit) model proposed by Agoram et al. (2001) . In the ACAT model the GI tract is divided into nine compartments, one for the stomach, seven for the small intestine and one for the colon, and the absorption process is described using a set of over 80 differential equations. The ACAT model uses compound specific parameters like permeability, solubility and dose, as well as physiological information as species, GI transit time, food status, etc. A detailed overview of these two methods is given by Parrott and Lavé (2002) , and the link between drug absorption and the permeability and the solubility is discussed by Pade and Stavhansky (1998) . The OraSpotter T M program, uses information about the molecular structure only, which are turned into SMILES. The descriptors are then evaluated from the SMILES. Parrott and Lavé (2002) developed models for the intestinal absorption using IDEA T M 2.0 and GastroPlus T M 3.1.0. They used three approaches in their work: 1) Prediction of absorption class using chemical structure data only. 2) Predictions based upon measured solubility and predicted permeability. 3) Predictions based upon measured solubility and measured CACO-2 permeability. The RMS deviations were in the range of 19-24% for the models developed, and the best model was obtained with the IDEA program, using both measured solubility and measured permeability. However, the IDEA and GastroPlus programs gave fairly similar results in this study. Wessel et al. (1998) developed a QSPR type model, using non-linear GA/NN techniques, for prediction of human intestinal absorption, based on Caco-2 measurements of permeability. The data set used contains measured values for 86 drug and drug-like compounds, selected from various sources. The descriptors used were generated with the ADAPT (Automated Data Analysis and Pattern Recognition Toolkit) software, the MOPAC program using the AM1 semi-empirical quantum chemical method, derived from 2D structures using graph theory, and by using substructure fragments. A fairly good model, with RMS deviation of 16%, was obtained. Palm et al. (1998) evaluated the relationship between various molecular descriptors and transport of drugs across the intestinal epithelium, also using measurements for Caco-2 cells, and Clark (1999) developed a method using the polar molecular surface area of the molecules as a descriptor. A minimalistic model based on the 'rule of five' was proposed by Oprea and Gottfries (1999) , Zamora et al. (2001) used chemometrics methods for predicting drug permeability, and new QSAR models were proposed by Kulkarni et al. (2002) . Egan and Lauri (2002) published a review on methods for prediction of passive intestinal permeability.
Blood-brain barrier penetration
The BBB separates the brain from the systemic blood circulation. Passage through the BBB is a necessity for orally administrated drugs targeting receptors and enzymes in the central nervous system (CNS), whereas generally it is an unwanted property for peripherally acting drugs. BBB penetration is usually expressed as logBB = log(C brain /C blood ), i.e. the logarithm to the ratio between the concentration of the drug in the brain and in the blood, respectively. Experimental logBB values range between -2.0 and +1.0 and compounds with logBB > 0.3 are characterized as BBB penetrating whereas compounds with logBB < -1.0 are poorly distributed to the brain.
One of the first attempts to predict BBB penetration dates back to 1988, where Young et al. (1988) obtained a correlation between logBB and logP or derivatives of logP for a small series of histamine H2 antagonists. In the following years a number of models for BBB penetration were published, and these models are discussed in recent reviews (Ekins et al., 2000; Norinder and Haeberlein, 2002) . In the following we will focus on more recently reported models. Nearly all models developed until year 2000 were based on a relatively small number of compounds (57-65 compounds) with a limited structural diversity, including several compounds being far from drug-like. Kelder et al. (1999) expanded the number of available compounds by reporting logBB for additional 45 drug like compounds. In addition to developing models for BBB penetration, they also showed that CNS active drugs could be distinguished from non-CNS active drugs based on their polar surface area. Jørgensen et al. (2001) presented a model based on all available BBB penetration data at that time (105 compounds). They based their model on an atom-weighted surface area approach, where the contribution of each atom to the BBB penetration depended on the atom type and its solvent accessibility. Rose et al. (2002) developed a model for the same set of compounds using electrotopological state descriptors, whereas Kaznessis et al. (2001) generated a number of physically significant descriptors from Monte Carlo simulations in water and used those in a model for BBB penetration. Hou and Xu (2002) developed a model using GA and Feher et al. (2000) proposed a very simple model based on only three descriptors, logP , number of hydrogen bonds and polar surface areas. It appears that these descriptors, or related descriptors, describe the structural requirements for BBB penetration most effectively (Norinder and Haeberlein, 2002) .
It is interesting that the quantitative models for prediction of BBB penetration, although based on very different methods, yielded comparable results. This probably reflects the relatively small number of compounds included in the modeling, the lack of structural diversity, as well as uncertainties associated with the experimental logBB values. Several drug molecules are actively transported across membranes, including the BBB, by various transporters which may include active transport to the CNS as well as efflux transporters (Bodor and Buchwald, 1999; Kusuhara and Sugiyama, 2002; Sun et al., 2002) .
A number of models for classification of compounds as CNS active or CNS inactive have been published. An NN based on 2D Unity fingerprints was developed by Keserû et al. (2000) for identification of CNS active compounds in virtual HTS. Engkvist et al. (2003) showed that a model based on substructure analysis performed as well as a more complex NN based model. Doniger et al. (2002) developed and compared an NN and a support vector machine approach. Crivori et al. (2000) published a method for classification of compounds as CNS active or CNS inactive, respectively. The model used descriptors from 3D molecular interaction fields generated by VolSurf and multivariate statistical methods for the subsequent data analysis. Based on a test set of 110 molecules the model predicted logBB correctly 90% for an external set of 120 compounds. In a recent paper by Wolohan and Clark (2003) the combination of descriptors developed from interaction fields and subsequently analyzed by multivariate statistics were further developed and applied not only for prediction of BBB penetration but addressing the more general problem of oral bioavailability.
Other ADMET properties Metabolism of drugs in the gut wall and in the liver is a major issue, where reactions due to cytochrome P450 liver enzymes are of particular importance (Lewis, 1996) . Metabolism of xenobiotics is very complicated and thus difficult to model adequately. Nicholson and Wilson (2003) recently published a review article on xenobiotic metabolism, and de Groot and and Lewis and Dickins (2002) published a review on metabolism through cytochrome P450 dependent reactions. Langowski and Long (2002) studied various enzyme modeling systems, databases, and expert systems for prediction of xenobiotic metabolism. They discussed three expert systems, META Talafous et al., 1994; Klopman et al., 1997) , MetabolExpert and METEOR (Greene et al., 1997; Buttom et al., 2003) , and two enzyme modeling systems. Enzymatic reactions are primarily studied using various molecular modeling methods, and as it is not a central chemoinformatics problem it is outside the scope of this paper.
Toxicity of drugs is another extremely important problem, leading to a significant number of drug failures. Greene (2002) published a review paper about a number of commercial prediction systems, including DEREK (Greene et al., 1997; Judson et al., 2003) , OncoLogic (Dearden et al., 1997) , HazardExpert, COMPACT (Parke et al., 1990) , CASE/Multi-CASE (Klopman, 1992) and TOPKAT. Katritzky et al. (2001) , Espinosa et al. (2002) and Tong et al. (2002) have developed QSAR models for the prediction of toxicity.
Up to now, not much effort has been put into in silico modeling of distribution of drugs within the human organism, and almost none on excretion. Experimental quantities which measure distribution of drugs in the human body adequately are not readily available, but according to Boobis et al. (2002) logP , octanol-water distribution coefficients (logD) and in vivo pharmacokinetic data can be used as a measure of distribution. Transporters, plasma-protein binding and other aspects of distribution are discussed by van de Waterbeemd and Gifford (2003) .
Physico-chemical properties
As mentioned above, physico-chemical properties of interest to drug discovery, are mainly acid-base dissociation constants (pK a ), aqueous solubilities, octanol-water partition coefficients (logP ) and octanol-water distribution coefficients (logD). These properties are generally relatively well studied, and many predictive methods are available in the literature. Recently, van de Waterbeemd (2003) and Livingstone (2003) published reviews on physico-chemical properties relevant to the drug discovery process. Many relatively good models are available for logP , logD and pK a of drugs (van de Waterbeemd, 2003) , and a large number of in silico models have been developed for the aqueous solubility of drugs and drug-like compounds, as discussed in recent reviews by Blake (2000) , Husskonen (2001) and Jorgensen and Duffy (2002) . There is, however, continued interest in improved models for the solubility of drugs, due to the importance of this property. It is important to mention that the solubility relates to the solid phase and is significantly more difficult to model than the other physicochemical properties. Difficulties in modeling properties relating to the solid phase are discussed by Dyekjaer and Jónsdóttir (2003) .
Some of the available models for aqueous solubility of organic compounds are based on structure information only using NN (Huuskonen et al., 1998; Huuskonen, 2000; McElroy and Jurs, 2001; Yan and Gasteiger, 2003; Taskinen and Yliruusi, 2003; Wegner and Zell, 2003) and QSPR (Katritzky et al., 1998; Yaffe et al., 2001; Zhong and Hu, 2003) methods. Other models use experimental quantities like logP , melting points, heats of fusion and vapor pressures as descriptors (Ran et al., 2001; Sangvhi et al., 2003) , sometimes together with calculated structural descriptors (McFarland et al., 2001; Thompson et al., 2003) , and group contribution methods have also been developed (Kühne et al., 1995; Klopmann and Zhu, 2001 ). Traditionally solubility is calculated using equilibrium thermodynamics (Prausnitz et al., 1986) . Very accurate predictions can be obtained, but the physical parameters needed are only seldomly available for drugs and drug-like molecules. Jónsdóttir et al. (2002) have developed an in silico method, using molecular mechanics calculations.
To date, the research efforts have mainly been focused on the aqueous solubility of drugs, and very little attention has been devoted to their solubility in buffered solutions, and the pH dependence of solubility (Avdeef et al., 2000; Sangvhi et al., 2003) . For understanding dissolution of drugs in the human organism it is crucial to focus increasingly on solubility in a more realistic environment, and to acquire larger amounts of experimental data for the pH dependence of solubility.
ROLE OF DATABASES AND CHEMOINFORMATICS IN FUTURE DRUG DISCOVERY
As documented in this review, chemoinformatics is a rapidly growing field which has become extremely important in pharmaceutical research in the last couple of years. The generation, storage, retrieval and utilization of data related to chemical structures has merged established disciplines and catalyzed the development of new techniques. Thus, chemoinformatics bridges established areas like molecular modeling, computational chemistry, statistics and bioinformatics, and is closely related to other emerging fields as chemogenomics, metabonomics and pharmacogenomics.
Chemoinformatics methods are already used extensively in the drug discovery and development process by the pharmaceutical industry, and many powerful methods have been proposed. The predictive methods available are of various quality and complexity ranging from simple rulesof-thumb to sophisticated 3D methods involving simulation of ensembles of molecules containing thousands of atoms. In the years to come, improved in silico methods for prediction of properties based on structural information will merge, and be used to assist in identifying more suitable hits and leads.
Structural and property databases provide the foundation of chemoinformatics and a variety of databases containing structurally derived data for organic compounds are available. Although the number of entries in a given database is often considered the most important measure of the quality or usability of a database, there is increased awareness concerning the quality of the data rather than on the number of entries.
The recent literature presents a number of methods for the classification of the drug-likeness of compounds based on subsets of molecules from databases representing druglike and non-drug-like molecules, respectively. Classification methods which predict the lead-likeness of molecules, or their affinity toward specific targets, would be even more useful, and thus the generation of databases of lead-like molecules, etc., is highly desired. All such methods are limited to likely drugs, but we could eventually gather information about non-drug-like drugs, and find common features in those as well.
To ensure good predictive power of such models, the redundancy of the data sets used for training and testing the model is crucial. It is thus very important to balance the data in such a way that certain structural features are not over-represented. Researchers using many other databases, e.g. protein structure databases, have encountered a similar problem. They realized that the use of all available 3D protein structures in PDB for analyzing and extracting loops, motifs, side-chains etc. could be problematic due to the over-representation of some proteins or protein families relative to others. Accordingly, a number of data sets of non-homologous protein structures have been developed. Also, much focus has been devoted into in silico modeling of ADMET and physico-chemical properties of drugs and drug candidates. A variety of different methods for prediction of relevant physico-chemical properties, like logP , pK a and aqueous solubility, of organic compounds are available, and in general these methods perform satisfactorily considering the data available. In the case of the aqueous solubility, a large number of methods have been developed, and there is continued interest in this property. The effect of the pH value of the solution on solubility needs to be studied in much greater detail.
Concerning ADMET properties, a number of in silico models have been proposed for intestinal absorption and blood-brain barrier penetration, some models for metabolism and toxicity and only very few models for distribution and excretion. The total number of data available for a certain end point often limits the possibility for developing improved predictive models for ADMET properties. Permeability of the blood-brain barrier is such a case, where measured values are only available for a little more than one hundred compounds. The lack of structural diversity within these compounds is another limiting factor.
Properties like metabolism, oral bioavailability, etc. of drugs within the human organism involve several individual processes, and thus sub-processes and bottlenecks governing these processes need to be identified. Due to lack of reliable data, combined with a very complex mode of action of the processes involved, the present methods often fail. In some case where a method yields promising results for a set of compounds, the transferability of the method to another series or class of compounds may be questionable. Within this area there is much need for developing better and more robust predictive methods, but there is also a need for determining and collecting larger amount of experimental data for the individual processes.
The oral bioavailability is a particularly difficult property to model as it involves huge number of processes within the human organism, and depends on all the ADMET and physico-chemical properties discussed above. The molecule has to dissolve, be adsorbed into the bloodstream, transported to the target, and not metabolized on its way. Thus for an orally administrated drug to reach its final destination, a whole range of properties need to be within acceptable limits, and thus a model which defines such limits would be very useful. Dynamic modeling of processes within living cell with systems biology methods is growing rapidly, which is expected to have a huge impact on future drug design, and in particular on the modeling of the oral bioavailability. As discussed by Parsons et al. (2004) chemical-genetic and genetic interaction profiles can potentially be integrated to provide information about the pathways and targets affected by bioactive compounds. Such methods could thus be very useful for identifying mechanism of action and cellular targets of bioactive compounds. Improved understanding of how different drugs affect one another within the human organism is also of great importance, and thus much interest is presently devoted to studies of drug-drug interactions. An extremely exiting perspective is of course also to use pharmacogenomics methods for examining how individual patients respond to specific drugs, and how that depends on their genetic makeup.
Although more data, better data and an improved understanding of the interplay between the different processes in the human organism are required, the present level of available data has already made chemoinformatics an effective tool in the drug discovery and development process.
The National Cancer Institute database (NCI) is publicly available
